

2022 ACCP/ASHP BCOP Clinical Sessions

Learning Objectives

Taking a Deeper Dive: The Utilization of ctDNA and Minimal Residual Disease (MRD) to Assess Anticancer Therapeutic Response in Cancer

1. Compare differences in the technologies utilized in solid tumor genomic profiling (tissue vs. plasma).
2. Assess the utility of measuring serial plasma cell-free (ctDNA) in therapy response assessment.
3. Describe minimal residual disease (MRD) testing methods.
4. Evaluate the impact and challenges of MRD in hematologic malignancies.

The Alphabet Soup of Hematologic Disorders: Background and Treatment Updates in ITP, TTP, HUS, and DIC

1. Illustrate understanding of the basic pathophysiology of immune thrombocytopenia (ITP), thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome (HUS), and disseminated intravascular coagulation (DIC) and their associated drug therapies.
2. Examine patients' medication lists to identify common medications (including cancer treatments, immunotherapies, and drugs from other classes) implicated in the development of bleeding disorders.
3. Compare and contrast pharmacologic standard-of-care and new therapies for the treatment of immune thrombocytopenia (ITP), thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome (HUS), and disseminated intravascular coagulation (DIC).
4. Show the relationship between COVID-19 (and COVID-19 vaccinations) and bleeding disorders, and how to approach the treatment of these disorders.
5. Demonstrate the critical role of the clinical pharmacist in the procurement and administration of pharmacologic therapies used to treat bleeding disorders.